TipRanks
MBX Biosciences, Inc. (MBX)
NASDAQ:MBX
US Market
MBX
MBX Biosciences, Inc.
RESEARCH TOOLSreports
Want to see MBX full AI Analyst Report?

MBX Biosciences, Inc. (MBX) Stock Forecast & Price Target

237 Followers
See the Price Targets and Ratings of:

MBX Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
MBX
Biosciences, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MBX Stock 12 Month Forecast

Average Price Target

$90.43
▲(35.45% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for MBX Biosciences, Inc. in the last 3 months. The average price target is $90.43 with a high forecast of $121.00 and a low forecast of $70.00. The average price target represents a 35.45% change from the last price of $66.76.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","122":"$122","40.25":"$40.3","67.5":"$67.5","94.75":"$94.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$90.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,40.25,67.5,94.75,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.93,65.55076923076923,70.17153846153846,74.79230769230769,79.41307692307691,84.03384615384616,88.65461538461538,93.27538461538461,97.89615384615385,102.51692307692306,107.1376923076923,111.75846153846155,116.37923076923076,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.93,63.199120879120876,65.46824175824176,67.73736263736264,70.00648351648351,72.2756043956044,74.54472527472528,76.81384615384616,79.08296703296703,81.35208791208791,83.6212087912088,85.89032967032966,88.15945054945055,{"y":90.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.93,61.62769230769231,62.325384615384614,63.02307692307692,63.72076923076923,64.41846153846154,65.11615384615385,65.81384615384616,66.51153846153846,67.20923076923077,67.90692307692308,68.60461538461539,69.30230769230769,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.92,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.93,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.93,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$121.00Average Price Target$90.43Lowest Price Target$70.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MBX
Jessica Fye
J.P. Morgan
J.P. Morgan
$88
Buy
31.82%
Upside
Initiated
08/21/26
MBX Biosciences reinstated with an Overweight at JPMorganMBX Biosciences reinstated with an Overweight at JPMorgan
Stifel Nicolaus Analyst forecast on MBX
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$70
Buy
4.85%
Upside
Reiterated
08/11/26
Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Septerna, Inc. (NASDAQ: SEPN) and Six Flags Entertainment Corporation (NYSE: FUN)
Truist Financial Analyst forecast on MBX
Srikripa Devarakonda
Truist Financial
Truist Financial
$70→$88
Buy
31.82%
Upside
Reiterated
08/10/26
MBX Biosciences price target raised to $88 from $70 at TruistMBX Biosciences price target raised to $88 from $70 at Truist
LifeSci Capital Analyst forecast on MBX
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$121
Buy
81.25%
Upside
Assigned
08/08/26
Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and MBX Biosciences, Inc. (NASDAQ: MBX)
Barclays Analyst forecast on MBX
Eliana Merle
Barclays
Barclays
$70→$88
Buy
31.82%
Upside
Reiterated
08/07/26
MBX Biosciences price target raised to $88 from $70 at BarclaysMBX Biosciences price target raised to $88 from $70 at Barclays
UBS Analyst forecast on MBX
Michael Yee
UBS
UBS
$60→$90
Buy
34.81%
Upside
Reiterated
07/24/26
MBX Biosciences price target raised to $90 from $60 at UBSMBX Biosciences price target raised to $90 from $60 at UBS
Guggenheim Analyst forecast on MBX
Seamus Fernandez
Guggenheim
Guggenheim
$88
Buy
31.82%
Upside
Reiterated
07/14/26
Wall Street Analysts Are Bullish on Top NA Picks
Oppenheimer Analyst forecast on MBX
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$80
Buy
19.83%
Upside
Reiterated
06/15/26
Oppenheimer Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
Citizens JMP Analyst forecast on MBX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$76→$86
Buy
28.82%
Upside
Reiterated
05/12/26
MBX Biosciences price target raised to $86 from $76 at CitizensMBX Biosciences price target raised to $86 from $76 at Citizens
TD Cowen Analyst forecast on MBX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Advancing Pipeline and Key Data Catalysts Drive Analyst’s Bullish View on MBX
Goldman Sachs Analyst forecast on MBX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$31.97
Sell
-52.11%
Downside
Initiated
12/04/25
MBX Biosciences initiated with a Sell at Goldman SachsMBX Biosciences initiated with a Sell at Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on MBX
Jessica Fye
J.P. Morgan
J.P. Morgan
$88
Buy
31.82%
Upside
Initiated
08/21/26
MBX Biosciences reinstated with an Overweight at JPMorganMBX Biosciences reinstated with an Overweight at JPMorgan
Stifel Nicolaus Analyst forecast on MBX
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$70
Buy
4.85%
Upside
Reiterated
08/11/26
Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Septerna, Inc. (NASDAQ: SEPN) and Six Flags Entertainment Corporation (NYSE: FUN)
Truist Financial Analyst forecast on MBX
Srikripa Devarakonda
Truist Financial
Truist Financial
$70→$88
Buy
31.82%
Upside
Reiterated
08/10/26
MBX Biosciences price target raised to $88 from $70 at TruistMBX Biosciences price target raised to $88 from $70 at Truist
LifeSci Capital Analyst forecast on MBX
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$121
Buy
81.25%
Upside
Assigned
08/08/26
Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (NASDAQ: BLLN) and MBX Biosciences, Inc. (NASDAQ: MBX)
Barclays Analyst forecast on MBX
Eliana Merle
Barclays
Barclays
$70→$88
Buy
31.82%
Upside
Reiterated
08/07/26
MBX Biosciences price target raised to $88 from $70 at BarclaysMBX Biosciences price target raised to $88 from $70 at Barclays
UBS Analyst forecast on MBX
Michael Yee
UBS
UBS
$60→$90
Buy
34.81%
Upside
Reiterated
07/24/26
MBX Biosciences price target raised to $90 from $60 at UBSMBX Biosciences price target raised to $90 from $60 at UBS
Guggenheim Analyst forecast on MBX
Seamus Fernandez
Guggenheim
Guggenheim
$88
Buy
31.82%
Upside
Reiterated
07/14/26
Wall Street Analysts Are Bullish on Top NA Picks
Oppenheimer Analyst forecast on MBX
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
$80
Buy
19.83%
Upside
Reiterated
06/15/26
Oppenheimer Sticks to Its Buy Rating for MBX Biosciences, Inc. (MBX)
Citizens JMP Analyst forecast on MBX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$76→$86
Buy
28.82%
Upside
Reiterated
05/12/26
MBX Biosciences price target raised to $86 from $76 at CitizensMBX Biosciences price target raised to $86 from $76 at Citizens
TD Cowen Analyst forecast on MBX
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Advancing Pipeline and Key Data Catalysts Drive Analyst’s Bullish View on MBX
Goldman Sachs Analyst forecast on MBX
Corinne Johnson
Goldman Sachs
Goldman Sachs
$31.97
Sell
-52.11%
Downside
Initiated
12/04/25
MBX Biosciences initiated with a Sell at Goldman SachsMBX Biosciences initiated with a Sell at Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MBX Biosciences, Inc.

3 Months
Seamus FernandezGuggenheim
Success Rate
9/12 ratings generated profit
75%
Average Return
+46.58%
Copying Seamus Fernandez's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +46.58% per trade.
1 Year
Seamus FernandezGuggenheim
Success Rate
11/12 ratings generated profit
92%
Average Return
+112.27%
Copying Seamus Fernandez's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +112.27% per trade.
2 Years
Seamus FernandezGuggenheim
Success Rate
12/12 ratings generated profit
100%
Average Return
+125.85%
Copying Seamus Fernandez's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +125.85% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MBX Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
17
22
23
14
4
Buy
4
3
4
8
7
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
25
27
22
12
In the current month, MBX has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MBX average Analyst price target in the past 3 months is 90.43.
Each month's total comprises the sum of three months' worth of ratings.

MBX Financial Forecast

MBX Earnings Forecast

Next quarter’s earnings estimate for MBX is -$0.83 with a range of -$1.05 to -$0.69. The previous quarter’s EPS was -$0.78. MBX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.
Next quarter’s earnings estimate for MBX is -$0.83 with a range of -$1.05 to -$0.69. The previous quarter’s EPS was -$0.78. MBX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.
No data currently available

MBX Sales Forecast

Next quarter’s sales forecast for MBX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MBX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.
Next quarter’s sales forecast for MBX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. MBX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year MBX has Performed in-line its overall industry.

MBX Stock Forecast FAQ

What is MBX’s average 12-month price target, according to analysts?
Based on analyst ratings, MBX Biosciences, Inc.’s 12-month average price target is 90.43.
    What is MBX’s upside potential, based on the analysts’ average price target?
    MBX Biosciences, Inc. has 35.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MBX a Buy, Sell or Hold?
          MBX Biosciences, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is MBX Biosciences, Inc.’s price target?
            The average price target for MBX Biosciences, Inc. is 90.43. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $121.00 ,the lowest forecast is $70.00. The average price target represents 35.45% Increase from the current price of $66.76.
              What do analysts say about MBX Biosciences, Inc.?
              MBX Biosciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of MBX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.